圣安东尼奥 - 从事开发早期癌症检测非侵入性测试的生物技术公司bioAffinity Technologies, Inc. (NASDAQ:BIAF; BIAFW)已任命J. Michael Edwards为其首席财务官。Edwards自9月15日起担任临时首席财务官，为这一角色带来了超过30年的财务管理和商业战略经验。 Edwards在公司2022年首次公开募股中发挥了关键作用，他重返执行团队被 ...

Affinity Technologies has appointed J. Michael Edwards as Chief Financial Officer. Takeaway Points bioAffinity Technologies ...

Affinity Technologies today announced it appointed J. Michael Edwards as chief financial officer in September.

Affinity Technologies' CyPath® Lung test will be added to the Federal Supply Schedule to help veterans and active military at ...

More doctors are ordering bioAffinity Technologies' CyPath Lung test and sales are skyrocketing. A long-term military health ...

德克萨斯州圣安东尼奥 - 商业物理和生物研究服务公司bioAffinity Technologies, Inc. (NASDAQ:BIAF)今天宣布，其股东已批准在行使权证时发行股票。这一决定是在2024年10月2日举行的2024年特别股东大会上做出的。 这家总部位于德克萨斯州圣安东尼奥的公司确认，股东投票赞成两项提案。 第一项提案是批准在行使权证时发行最多1,801,944股普通股，这些权证是在 ...

Edwards will report directly to bioAffinity Technologies President and CEO Maria Zannes. "We are delighted to welcome Michael ...

CyPath Lung is a laboratory-developed assay that uses self-collected sputum samples treated with a fluorescent compound that preferentially binds to cancer cells and cancer-related cells, San ...

Noninvasive diagnostic test for lung cancer available to U.S. Veterans, other federal health services patients SAN ANTONIO, October 09, 2024--(BUSINESS WIRE)--bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that CyPath® ...

SAN ANTONIO, TX – bioAffinity Technologies, Inc. (NASDAQ:BIAF), a commercial physical and biological research services company, announced today that its shareholders have approved the issuance ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...